Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,390 Mln
Revenue (TTM)
$1,289 Mln
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
P/E Ratio
26.1
P/B Ratio
2.9
Industry P/E
--
EV/EBITDA
13.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$5.8
EPS
$0.7
Face value
--
Shares outstanding
81,902,232
CFO
$322.71 Mln
EBITDA
$155.93 Mln
Net Profit
$184.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Progyny (PGNY)
| -35.4 | -6.2 | -35.4 | -28.1 | -19.8 | -18.3 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Progyny (PGNY)
| 48.9 | -53.3 | 19.4 | -38.1 | 18.8 | 54.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Progyny (PGNY)
|
16.6 | 1,389.9 | 1,288.7 | 58.5 | 7.2 | 12.5 | 26.1 | 2.9 |
| 18.8 | 3,442.4 | 3,948.7 | -0.7 | 0.4 | -0.5 | -- | 19.8 | |
| 35.1 | 15,638.4 | 194,777.0 | -6,673.0 | -3.3 | -28.8 | -- | 0.8 | |
| 270.0 | 68,939.8 | 274,952.0 | 5,957.0 | 3.4 | 14.4 | 11.6 | 1.7 | |
| 1.7 | 902.4 | 1,924.3 | -85.6 | -4.4 | -26.3 | -- | 3.2 | |
| 300.7 | 62,854.5 | 199,125.0 | 5,662.0 | 4.1 | 13.3 | 11.3 | 1.5 | |
| 177.8 | 20,018.9 | 129,664.0 | 1,188.0 | 1.6 | 7 | 16.9 | 1.2 | |
| 0.0 | 0.0 | 10.8 | -31.2 | -259.9 | 1164.6 | -- | 8.9 | |
| 139.4 | 6,848.4 | 45,426.0 | 472.0 | 1.7 | 11 | 14.8 | 1.8 | |
| 277.3 | 237,620.5 | 447,567.0 | 12,056.0 | 4.2 | 12.9 | 19.8 | 2.5 |
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart... cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York. Address: 1359 Broadway, New York, NY, United States, 10018 Read more
Executive Chairman
Mr. David J. Schlanger
Executive Chairman
Mr. David J. Schlanger J.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Progyny Inc (PGNY) is $16.60 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Progyny Inc (PGNY) has given a return of -19.75% in the last 3 years.
The P/E ratio of Progyny Inc (PGNY) is 26.11 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
39.06
|
4.43
|
|
2024
|
30.16
|
3.88
|
|
2023
|
60.53
|
6.79
|
|
2022
|
102.61
|
8.26
|
|
2021
|
76.56
|
19.99
|
The 52-week high and low of Progyny Inc (PGNY) are Rs 28.75 and Rs 16.28 as of 03-Apr-2026.
Progyny Inc (PGNY) has a market capitalisation of $ 1,390 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Progyny Inc (PGNY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.26
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.